301089.SZ · 拓新药业
China A-shares · RS rating 63 · As of 2026-10-14
| Price | 23.39 CNY |
|---|---|
| 1-day change | -1.7% |
| RS rating (overall / 1M / 3M / 12M) | 63 / 83 / 67 / 32 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 33 / 24 / 25 |
| Industry group (rank) | Medical-Generic Drugs (40) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +28.4% |
| Distance from 52-week high | +32.1% |
| Market cap (USD) | $465.2M |